Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567783 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
A Phase 2 study, sponsored by Vir Biotechnology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,977
- Enrollment target
NCT05567783: Clinical Trial Phase 2 study, sponsored by Vir Biotechnology.
NCT05567783 is a Phase 2 study that was terminated before completion, run by Vir Biotechnology. The registered enrollment target is 2,977 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2138% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05567783, a Phase 2 study, was terminated before completion, sponsored by Vir Biotechnology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,977 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.
Primary Outcome
Protocol-defined ILI with confirmed influenza A defined as RT-PCR confirmed influenza A with at least one respiratory symptom and at least one systemic symptom
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VIR-2482 (450 mg)
- BIOLOGICAL VIR-2482 (1200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,977 participants |
| Start Date | 2022-10-30 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Why NCT05567783 stopped before completion
NCT05567783 is an interventional study that assigns participants to a tested intervention. Its 2,977 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2138% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05567783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05567783 about?
NCT05567783 is a clinical study titled "A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A". The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.
What is the current status of trial NCT05567783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,977 participants. The study started on 2022-10-30. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05567783?
The interventions under investigation include: Placebo (BIOLOGICAL), VIR-2482 (450 mg) (BIOLOGICAL), VIR-2482 (1200 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05567783?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05567783's enrollment target sits among peer trials
2,977 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI